Compare AIDX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIDX | DRMA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 5.6M |
| IPO Year | 2025 | 2021 |
| Metric | AIDX | DRMA |
|---|---|---|
| Price | $0.62 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 86.3K | ★ 478.7K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,045,133.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.71 | N/A |
| 52 Week Low | $0.40 | $0.95 |
| 52 Week High | $14.09 | $6.22 |
| Indicator | AIDX | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 59.20 |
| Support Level | $0.52 | $1.11 |
| Resistance Level | $0.70 | $1.62 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 86.29 | 75.76 |
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.